Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Primary mediastinal B-cell lymphoma (PMBL)

Written2016-09Luis Miguel Juárez Salcedo, Samir Dalia
Principe de Asturias University Hospital, Madrid, Spain (LMJS); Oncology and Hematology, Mercy Clinic Joplin, Joplin, MO, USA (SD); sdalia@gmail.com.

Abstract Review on primary mediastinal B-cell lymphoma, with data on clinics, and the genes involved.

Keywords primary mediastinal B-cell lymphoma; diffuse large B-cell lymphoma

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9679/3 Primary mediastinal (thymic) large B-cell lymphoma
Atlas_Id 1477
Other namesThymic large B-cell lymphoma
Primary mediastinal (thymic) large B-cell lymphoma
Mediastinal Large B-cell lymphoma

Clinics and Pathology

Disease PMBL is a subtype of diffuse large B-cell lymphoma (DLBCL) that arises in the thymus. It accounts for 2-4% on non-Hodgkin lymphoma and 10% of DLBCL. It is epidemiology, clinically and biologically distinct from the other subtypes of DLBCL. Similar to nodular sclerosis Hodgkin lymphoma (NSHL) arising in the mediastinum, it is likely derived from thymic B cells (Dunleavy et al., 2015)
Phenotype / cell stem origin An origin from medullary thymic B cells has been proposed for this disease.
PMBL has a B-cell phenotype and express CD20 and pan B-cell markers such as CD79a, CD 45, CD 19 and CD22, but tumor cells do not express surface immunoglobulin, therefore, monoclonality cannot be established by Κ and λ staining. B-cell transcription factors including PAX-5, OCT2 and BOB1 are typically strongly expressed. CD23 expression is present in almost 66% of cases; CD30 is expressed in 78% whereas CD 15 is usually negative, although one third of patients are positive. High expression of BCL2 and PD1 has been described (Bledsoe et al., 2016).
CD21 and class I and/or II histocompatibility molecules have been claimed to be absent. Bcl-2 protein seems to be generally expressed, while fragmentary data are available concerning the occurrence of some molecules, such as CD10, MUM1/IRF4, PAX5/BSAP (B-cell Specific Activating Protein), Bcl-6.
Epidemiology Typically presents in adolescents and young adults with a median age of 35 years and a female predominance with a male.female ratio of 1:2. (Gaulard et al., 2008).
Clinics PMBL is an aggressive disease manifested by a localized, bulky mediastinal mass, often with pleural and pericardial effusions.
Symptoms at diagnosis are caused by the mediastinal mass, and complications such as superior vena cava syndrome are common at presentation.
Regional lymph nodes may be involved, but spread to distant nodal sites is uncommon. Less frequent, the disease involves extranodal sites, including the lung, kidneys, gastrointestinal organs or brain.
Pathology Morphologically, the thymic B-cells are medium to large cells having round or lobulated nuclei and abundant cytoplasm. In most cases, compartmentalizing sclerosis is observed, and sometimes tumor cells can resemble Hodgkin/Reed Sternberg cells.
The nodal architecture is typically diffuse, with occasional cases showing focal nodularity, and necrosis is sometimes seen.
Treatment In making decisions about the initial treatment one must consider the long-term complications of mediastinal radiation in this population of patients who are predominantly young women.
R-CHOP followed by radiation has been effective in low-risk patients.
In high-risk disease and high rate of primary refractory disease DA- EPOCH-R without radiation is the best treatment option, followed or not of autologous stem cell transplantation.
Prognosis Although the international prognosis index (IPI) is useful in DLBCL, its use in PMBL could be limited by the young age distribution and its typical mediastinal presentation.
Lactate dehydrogenase level, male sex, performance status and advanced-stage disease may be useful predictors of survival.

Genetics

Among the most common genetic alterations in PMBL are abnormalities on chromosome 9p and 2p.
The 9p region encodes JAK2, which then activates the STAT6 through phosphorylation. This STAT 6 phosphorylated can transcriptionally repress BCL6. Also in 9p region, CD274 and PDCD1LG2 (programmed death ligands (PDLs) 1 and 2 respectively) are rearranged at a frequency of 20%.
Gains or amplifications of REL may be seen at 2p.
One third of cases may have gains in chromosome X.
New two recurrent mutations have been identified; one of these is the recurrent somatic coding-sequence mutation in the PTPN1 gene (also found in Hodgkin lymphoma cases) and the recurrent point mutation in the XPO1 (exportin 1 gene or CRM1), which results in the Glu571Lys missense substitution, in refractory/relapsed PMBL (Jardin et al., 2016).
The XPO1 mediate the translocation of numerous RNAs and cellular regulatory proteins, including tumor suppressor proteins (TP53, BRCA1, NPM1, APC and FOXO).

Bibliography

CNS involvement in primary mediastinal large B-cell lymphoma
Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC
J Clin Oncol 1999 Aug;17(8):2479-85
PMID 10561312
 
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41
PMID 27419920
 
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood
Dunleavy K, Wilson WH
2015 Jan 1;125(1):33-9 doi: 10
PMID 25499450
 
WHO Classification of Tumours of Hae-matopoietic and Lymphoid Tissues
Gaulard P, Harris NL, Pileri SA, et al. Primarymediastinal (thymic) large B-cell lymphoma.
In:Swerdlow SH, Campo E, Harris NL, Jaffe ES,Pileri SA, Stein H, Thiele J, Vardiman JW, editors. Lyon: IARCPress; 2008. pp 250-251.2.
 
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma
Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, Delarue R, Haioun C, Argueta C, Landesman Y, Salles G, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K
Am J Hematol 2016 Sep;91(9):923-30
PMID 27312795
 

Citation

This paper should be referenced as such :
Juárez Salcedo LM, Dalia S
Primary mediastinal B-cell lymphoma (PMBL);
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/PrimMediastiBLymphomID1477.html


Other genes implicated (Data extracted from papers in the Atlas) [ 5 ]

Genes FCER2 HTRA2 IRF4 SOCS1 TNFAIP3

External links

arrayMapMorph ( 9679/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databasePrimary mediastinal B-cell lymphoma (PMBL)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 30 11:22:37 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.